Influence of fludarabine on the pharmacokinetics of oral busulfan during pretransplant conditioning for hematopoietic stem cell transplantation

Journal of Clinical Pharmacology

Volumn 53, Issue 11, 2013, Pages 1205-1211

  De Castro, Francine Attié ^a   Lanchote, Vera Lucia ^a   Voltarelli, Julio Cesar ^a   Colturato, Virgílio Antônio Rensi ^b   Simões, Belinda Pinto ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Hospital Amaral Carvalho   (Brazil)

Author keywords

Busulfan; Fludarabine; Hematopoietic stem cell transplantation; Pharmacokinetics

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE;

ACUTE BIPHENOTYPIC LEUKEMIA; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MONITORING; FEMALE; GRAFT VERSUS HOST REACTION; HEMORRHAGIC CYSTITIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER VENOOCCLUSIVE DISEASE; LUNG INFECTION; LUNG TOXICITY; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; SEPTIC SHOCK; TIME TO MAXIMUM PLASMA CONCENTRATION; YOUNG ADULT;

BUSULFAN; FLUDARABINE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; PHARMACOKINETICS;

ADOLESCENT; ADULT; ALKYLATING AGENTS; BUSULFAN; CYCLOPHOSPHAMIDE; DRUG INTERACTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; TRANSPLANTATION CONDITIONING; VIDARABINE; YOUNG ADULT;

EID: 84892926641     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.130     Document Type: Article

References (31)

1. Perkins JB, Kim J, Anasetti C, et al. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18:1099-1107.
2. Maradei SC, Maiolino A, Azevedo AM, Colares M, Bouzas LF, Nucci M. Serum ferritin as risk for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation. Blood. 2009;114:1270-1275.
3. Malär R, Sjöö F, Rentsch K, Hassan M, Güngör T. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients. Pediatr Transplant. 2011;15: 580-588.
4. Geddes M, Kangarloo SB, Naveed F, et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant. 2008;14:220-228.
5. Nath CE, Earl JW, Pati N, Stephen K, Shaw PJ. Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients. Br J Clin Pharmacol. 2008;66:50-59.
6. McCune JS, Gibbs, JP, Slattery JT. Plasma concentration monitoring of busulfan: Does it improve clinical outcome Clin Pharmacokinet. 2000;39:155-165.
7. Kim SD, Lee JH, Hur EH, et al. Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17:1222-1230.
8. Elhasid R, Krivoy N, Rowe JM, et al. Influence of glutathione Stransferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2010;55:1172-1179.
9. Kashyap A, Wingard J, Cagnoni P, et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: Decreased incidence of hepatic venoocclusive disease (HVOD), HVODrelated mortality, and overall 100day mortality. Biol Blood Marrow Transplant. 2002;8:493-500.
10. Gibbs JP, Liacouras CA, Baldassano RN, Slattery JT. Upregulation of glutathione Stransferase activity in enterocytes of young children. Drug Metab Dispos. 1999;27:1466-1469.
11. Gibbs JP, Murray G, Risler L, Chien JY, Dev R, Slattery JT. Agedependent tetrahydrothiophenium ion formation in young children and adults receiving highdose busulfan. Cancer Res. 1997;57:5509-5516.
12. Krivoy N, Zuckerman T, Elkin H, et al. Pharmacokinetic and pharmacogenetic analysis of oral busulfan in stem cell transplantation: Prediction of poor drug metabolism to prevent drug toxicity. Current Drug Safety. 2012, 7:211-217.
13. ten Brink M, Wessels J, den Hartigh J, et al. Effect of genetic polymorphisms in genes encoding GST isoenzymes on BU pharmacokinetics in adult patients undergoing hematopoietic SCT. Bone Marrow Transplant. 2012, 47:190-195.
14. Abbasi N, Vadnais B, Pharm B, et al. Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients. J Clin Pharmacol. 2011, 51:1429-1438.
15. Browning B, Thormann K, Donaldson A, Halverson T, Shinkle M, Kletzel M. Busulfan dosing in children with BMI-85% undergoing HSTC: A new optimal strategy. Biol Blood Marrow Transplant. 2011;17:1383-1388.
16. Yeh RF, Pawlikowski MA, Blough DK, et al. Accurate targeting of daily intravenous busulfan with 8hour blood sampling in hospitalized adult hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2012;18:265-272.
17. O'Donnell PH, Artz AS, Undevia SD, et al. Phase I study of doseescalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: Reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/venoocclusive disease. Leuk Lymphoma. 2010;51:2240- 2249.
18. Shimoni A, Nagler A. Increasing the dose intensity of the conditioning regimen prior to allogeneic hematopoietic stem cell transplant: The role of pharmacokinetic monitoring. Leuk Lymphoma. 2010;51:2154-2156.
19. Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15:523-536.
20. Vassal G, Michel G, Esperou H, et al. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol. 2008;61:113-123.
21. Shaw PJ, Scharping CE, Brian RJ, Earl JW. Busulfan pharmacokinetics using a single daily highdose regimen in children with acute leukemia. Blood. 1994;84:2357-2362.
22. Yeager AM, Wagner JE Jr, Graham ML, Jones RJ, Santos GW, Grochow LB. Optimization of busulfan dosage in children undergoing bone marrow transplantation: A pharmacokinetic study of dose escalation. Blood. 1992;80:2425-2428.
23. McCune JS, Baker KS, Blough DK, et al. Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients. J Clin Pharmacol. 2013;53:264-275.
24. de Lima M, Couriel D, Thall PF, et al. Oncedaily intravenous busulfan and fludarabine: Clinical and pharmacokinetic results of a myeloablative, reducedtoxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004;104: 857-864.
25. Liu H, Zhai X, Song Z, et al. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: A prospective and multicenter study. J Hematol Oncol. 2013;6:15.
26. Almog S, Kurnik D, Shimoni A, et al. Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination. Biol Blood Marrow Transplant. 2011;17: 117-123.
27. Shaw PJ, Nath C, Berry A, Earl JW. Busulphan given as four single daily doses of 150 mg/m2 is safe and effective in children of all ages. Bone Marrow Transplant. 2004;34:197-205.
28. Bonin M, Pursche S, Bergeman T, et al. FaraA pharmacokinetics during reducedintensity conditioning therapy with fludarabine and busulfan. Biol Blood Marrow Transplant. 2007; 39:201-206.
29. Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet. 2002;41:93-103.
30. Nath CE, Shaw PJ. Busulphan in blood and marrow transplantation: Dose, route, frequency and role of therapeutic drug monitoring. Curr Clin Pharmacol. 2007;2:75-91.
31. Rooseboom M, Commandeur JN, Vermeulen NP. Enzymecatalyzed activation of anticancer prodrugs. Pharmacol Rev. 2004; 56:53-102.